Christian Hinrichs
@CSHinrichsMD
Followers
744
Following
182
Media
23
Statuses
341
Chief, Cancer Immunotherapy Section Rutgers Cancer Institute of New Jersey (personal account)
United States
Joined June 2017
Rutgers Cancer Institute of New Jersey Receives $25 Million Gift for Cancer Immunology and Metabolism Center of Excellence | Rutgers University
rutgers.edu
4
2
33
NOW OPEN @RutgersCancer: “A Phase I Trial of T Cell Receptor Gene Therapy Targeting KK-LC-1 for Cancers of the Stomach, Breast, Lung and Cervix.” #ClinicalTrial #CancerResearch @CSHinrichsMD @RWJBarnabas
https://t.co/YL3m8TrXCY
0
4
8
A big thank you to @RutgersWBB coach Coquese Washington @CoqueseWashing and @RutgersWBB Chief of Staff Stephen Fishler @StephenFishler1 for visiting us at @RutgersCancer today! 🏀 @RWJBarnabas @RUAthletics @DrAEvens @slibutti
0
4
20
NOW OPEN @RutgersCancer: “A Phase II Trial of T Cell Receptor Gene Therapy Targeting HPV-16 E7 for HPV-Associated Cancers” @CSHinrichsMD #ClinicalTrial #CancerResearch @RWJBarnabas
https://t.co/Iexc3S1jY0
0
1
4
NOW OPEN @RutgersCancer: “A Phase I Trial of T Cell Receptor Gene Therapy Targeting KK-LC-1 for Cancers of the #Stomach, #Breast, #Lung and Cervix.” #ClinicalTrial #CancerResearch @CSHinrichsMD @RWJBarnabas #BCSM
https://t.co/YL3m8TrXCY
0
1
3
NOW OPEN @RutgersCancer: “A Phase I Trial of T Cell Receptor Gene Therapy Targeting KK-LC-1 for Cancers of the Stomach, Breast, Lung and Cervix.” #ClinicalTrial #CancerResearch @CSHinrichsMD @RWJBarnabas
https://t.co/YL3m8TrXCY
0
3
4
NOW OPEN @RutgersCancer: “A Phase II Trial of T Cell Receptor Gene Therapy Targeting HPV-16 E7 for HPV-Associated Cancers” @CSHinrichsMD
#ClinicalTrial #CancerResearch #HPV #hpvvaccine @RWJBarnabas
https://t.co/vLU1Hz5R1f
0
5
10
In this Perspective, we consolidate lessons from clinical experience and describe key issues going forward in the development of cell therapy for epithelial cancers.
0
1
3
Thanks to Tracie Saunders RN, OHRS Exec Dir reporting on our new cellular therapy #clinicaltrials for solid tumors, working with Dr @CSHinrichsMD. Latest in TCR cell therapy now @RutgersCancer @RWJBarnabas
0
2
6
Work by John Davies finding in multiple solid tumor T cell therapy models that PD-1 blockade acts through endogenous rather than transferred T cells to mediate a non-synergistic anti-tumor effect. It will be interesting to see clinical data from the many active studies.
New #JITC article: Non-synergy of PD-1 blockade with T-cell therapy in solid tumors https://t.co/31mPycMgNK
@gulleyj1 @CSHinrichsMD
0
1
5
@NCICancerBio 1/2 Cell Therapy, approved for heme malignancies, is now demonstrating activity in solid tumors. Our collaboration with @CSHinrichsMD has demonstrated amazing response rates in #HPV associated cancers with TCR engineered T-cells. https://t.co/ZukuJoJLDx
#CIM22 #CIMChat22
nature.com
Nature Medicine - In a first-in-human phase 1 trial of patients with HPV-associated metastatic epithelial cancers, T cells targeting HPV-16 E7 were well tolerated, with one observed dose-limiting...
0
2
8
What a great honor to celebrate with so many friends!
Eileen White of @RutgersU is being inducted as a member of the National Academy of Sciences for research on the mechanisms required for tumors to survive, proliferate, and evade surveillance by the immune system. Watch the #NAS159 livestream: https://t.co/SCLHy5ntRV
34
18
344
🙌 A big welcome to Ira Braunschweig, MD, as the new Chief of the Section of Transplant and Cell Therapy at @RutgersCancer & Chief of the Transplant and Cell Therapy Service at @RWJBarnabas Oncology Service Line: https://t.co/prUX9N5Xmh.
#CellTherapy #BMT #LetsBeatCancerTogether
2
4
20
From diagnosis, to treatment, to survivorship, the @RutgersCancer @RWJBarnabas Jack & Sheryl Morris Cancer Center will serve as a beacon of hope & destination for those who need it most. The 12 story, 510,000 s.f. facility is set for completion in 2024! https://t.co/vJLKHeQFdS
0
3
23
#ASHKudos to @RWJUH @RutgersCancer Heme/Onc fellow Dr Jiequi (Janice) Liu for leading the multicenter RWE project of CD19 #CART Therapy in Solid Organ Transplant (SOT)-Related #PTLD; it provides the largest analysis to date of CD19 CAR-T SOT-related PTLD. https://t.co/2jLL1tvnvg
We're pleased to give a hearty #ASHKudos to the 2021 ASH Abstract Achievement Awardees who will present at #ASH21! We'd like to give a special congrats to this year's Outstanding Abstract Achievement Awardees. Learn more about these awardees here: https://t.co/ZzJC8KlmZZ
1
4
21
.@RutgersCancer is seeking a nationally recognized research-focused pathologist to serve as the Chief of Cancer Pathology and Director of the Biorepository &Histopathology Service at Rutgers Cancer Institute. For more details please visit: https://t.co/FpknGSFx9w
0
1
3
Excited to share our work on the potential role of preventative immunotherapy in high risk oral leukoplakia 🧐👀🩺 @DanaFarberNews @DrUppaluri @bmsnews @SookbinWoo @HNOPDFCI @AACR
Inaugural papers: Glenn Hanna et al. establish PD-L1 as a biomarker of high risk for malignant transformation of oral leukoplakia, suggesting immune checkpoint blockade as a potential preventative treatment. https://t.co/b9ZcyOevHJ
@HeadNeckMD
@DanaFarber @BrighamWomens
0
6
25
Such an honor to work with the incredibly dedicated team at JITC, lead by Dr. Romero. ❤️Love our mission. Efficiently and effectively sharing meaningful new discoveries to impact the lives of patients with cancer.
Congratulations to the recipients of these noteworthy awards! Special kudos to our editors, Drs. Demaria, Formenti, and Gulley. Thank you, @gulleyj1, 2021 Pedro J. Romero Service to #JITC Award recipient, for your exceptional service and support of JITC @WeillCornell @theNCI
2
2
20
We are pleased to announce Dr. Kevin David as the new director of the Lymphoma Program @RutgersCancer! Dr. David leads a multidisciplinary team of experts who provide exceptional expertise, knowledge & skill with advanced therapies to treat #lymphoma. @RWJBarnabas @RWJMS
1
3
22
Center of Excellence for Cancer Immunology and Metabolism @RutgersCancer is seeking exceptional cancer immunologists https://t.co/GiedQ2TLeA & tumor immunology researchers https://t.co/ZI9Q2ufGR8 to join our @TheNCI-Designated Comprehensive Cancer Center!
0
3
7
1
3
26